FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361823150> ?p ?o ?g. }

• W4361823150 abstract "<div>Abstract<p>Inflammatory breast cancer (IBC) is a difficult-to-treat disease with poor clinical outcomes due to high risk of metastasis and resistance to treatment. In breast cancer, CD44⁺CD24⁻ cells possess stem cell-like features and contribute to disease progression, and we previously described a CD44⁺CD24⁻pSTAT3⁺ breast cancer cell subpopulation that is dependent on JAK2/STAT3 signaling. Here we report that CD44⁺CD24⁻ cells are the most frequent cell type in IBC and are commonly pSTAT3⁺. Combination of JAK2/STAT3 inhibition with paclitaxel decreased IBC xenograft growth more than either agent alone. IBC cell lines resistant to paclitaxel and doxorubicin were developed and characterized to mimic therapeutic resistance in patients. Multi-omic profiling of parental and resistant cells revealed enrichment of genes associated with lineage identity and inflammation in chemotherapy-resistant derivatives. Integrated pSTAT3 chromatin immunoprecipitation sequencing and RNA sequencing (RNA-seq) analyses showed pSTAT3 regulates genes related to inflammation and epithelial-to-mesenchymal transition (EMT) in resistant cells, as well as PDE4A, a cAMP-specific phosphodiesterase. Metabolomic characterization identified elevated cAMP signaling and CREB as a candidate therapeutic target in IBC. Investigation of cellular dynamics and heterogeneity at the single cell level during chemotherapy and acquired resistance by CyTOF and single cell RNA-seq identified mechanisms of resistance including a shift from luminal to basal/mesenchymal cell states through selection for rare preexisting subpopulations or an acquired change. Finally, combination treatment with paclitaxel and JAK2/STAT3 inhibition prevented the emergence of the mesenchymal chemo-resistant subpopulation. These results provide mechanistic rational for combination of chemotherapy with inhibition of JAK2/STAT3 signaling as a more effective therapeutic strategy in IBC.</p>Significance:<p>Chemotherapy resistance in inflammatory breast cancer is driven by the JAK2/STAT3 pathway, in part via cAMP/PKA signaling and a cell state switch, which can be overcome using paclitaxel combined with JAK2 inhibitors.</p></div>" @default.
• W4361823150 created "2023-04-05" @default.
• W4361823150 creator A5003496062 @default.
• W4361823150 creator A5007303016 @default.
• W4361823150 creator A5010743762 @default.
• W4361823150 creator A5013962113 @default.
• W4361823150 creator A5014395742 @default.
• W4361823150 creator A5014715325 @default.
• W4361823150 creator A5016056400 @default.
• W4361823150 creator A5019153476 @default.
• W4361823150 creator A5028610540 @default.
• W4361823150 creator A5029917436 @default.
• W4361823150 creator A5031509981 @default.
• W4361823150 creator A5031703305 @default.
• W4361823150 creator A5034493893 @default.
• W4361823150 creator A5039189570 @default.
• W4361823150 creator A5040107740 @default.
• W4361823150 creator A5041427080 @default.
• W4361823150 creator A5045021638 @default.
• W4361823150 creator A5045141452 @default.
• W4361823150 creator A5047880272 @default.
• W4361823150 creator A5050622020 @default.
• W4361823150 creator A5051852536 @default.
• W4361823150 creator A5058141992 @default.
• W4361823150 creator A5059869222 @default.
• W4361823150 creator A5066070097 @default.
• W4361823150 creator A5070797070 @default.
• W4361823150 creator A5073085049 @default.
• W4361823150 creator A5079240322 @default.
• W4361823150 creator A5079727834 @default.
• W4361823150 creator A5081145734 @default.
• W4361823150 creator A5081403443 @default.
• W4361823150 creator A5085614043 @default.
• W4361823150 creator A5085911788 @default.
• W4361823150 creator A5091861581 @default.
• W4361823150 date "2023-03-31" @default.
• W4361823150 modified "2023-09-27" @default.
• W4361823150 title "Data from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States" @default.
• W4361823150 doi "https://doi.org/10.1158/0008-5472.c.6514263.v1" @default.
• W4361823150 hasPublicationYear "2023" @default.
• W4361823150 type Work @default.
• W4361823150 citedByCount "0" @default.
• W4361823150 crossrefType "posted-content" @default.
• W4361823150 hasAuthorship W4361823150A5003496062 @default.
• W4361823150 hasAuthorship W4361823150A5007303016 @default.
• W4361823150 hasAuthorship W4361823150A5010743762 @default.
• W4361823150 hasAuthorship W4361823150A5013962113 @default.
• W4361823150 hasAuthorship W4361823150A5014395742 @default.
• W4361823150 hasAuthorship W4361823150A5014715325 @default.
• W4361823150 hasAuthorship W4361823150A5016056400 @default.
• W4361823150 hasAuthorship W4361823150A5019153476 @default.
• W4361823150 hasAuthorship W4361823150A5028610540 @default.
• W4361823150 hasAuthorship W4361823150A5029917436 @default.
• W4361823150 hasAuthorship W4361823150A5031509981 @default.
• W4361823150 hasAuthorship W4361823150A5031703305 @default.
• W4361823150 hasAuthorship W4361823150A5034493893 @default.
• W4361823150 hasAuthorship W4361823150A5039189570 @default.
• W4361823150 hasAuthorship W4361823150A5040107740 @default.
• W4361823150 hasAuthorship W4361823150A5041427080 @default.
• W4361823150 hasAuthorship W4361823150A5045021638 @default.
• W4361823150 hasAuthorship W4361823150A5045141452 @default.
• W4361823150 hasAuthorship W4361823150A5047880272 @default.
• W4361823150 hasAuthorship W4361823150A5050622020 @default.
• W4361823150 hasAuthorship W4361823150A5051852536 @default.
• W4361823150 hasAuthorship W4361823150A5058141992 @default.
• W4361823150 hasAuthorship W4361823150A5059869222 @default.
• W4361823150 hasAuthorship W4361823150A5066070097 @default.
• W4361823150 hasAuthorship W4361823150A5070797070 @default.
• W4361823150 hasAuthorship W4361823150A5073085049 @default.
• W4361823150 hasAuthorship W4361823150A5079240322 @default.
• W4361823150 hasAuthorship W4361823150A5079727834 @default.
• W4361823150 hasAuthorship W4361823150A5081145734 @default.
• W4361823150 hasAuthorship W4361823150A5081403443 @default.
• W4361823150 hasAuthorship W4361823150A5085614043 @default.
• W4361823150 hasAuthorship W4361823150A5085911788 @default.
• W4361823150 hasAuthorship W4361823150A5091861581 @default.
• W4361823150 hasBestOaLocation W43618231502 @default.
• W4361823150 hasConcept C121608353 @default.
• W4361823150 hasConcept C126322002 @default.
• W4361823150 hasConcept C1491633281 @default.
• W4361823150 hasConcept C153911025 @default.
• W4361823150 hasConcept C2779492189 @default.
• W4361823150 hasConcept C2780932548 @default.
• W4361823150 hasConcept C502942594 @default.
• W4361823150 hasConcept C530470458 @default.
• W4361823150 hasConcept C54355233 @default.
• W4361823150 hasConcept C71924100 @default.
• W4361823150 hasConcept C86803240 @default.
• W4361823150 hasConceptScore W4361823150C121608353 @default.
• W4361823150 hasConceptScore W4361823150C126322002 @default.
• W4361823150 hasConceptScore W4361823150C1491633281 @default.
• W4361823150 hasConceptScore W4361823150C153911025 @default.
• W4361823150 hasConceptScore W4361823150C2779492189 @default.
• W4361823150 hasConceptScore W4361823150C2780932548 @default.
• W4361823150 hasConceptScore W4361823150C502942594 @default.
• W4361823150 hasConceptScore W4361823150C530470458 @default.
• W4361823150 hasConceptScore W4361823150C54355233 @default.
• W4361823150 hasConceptScore W4361823150C71924100 @default.
• W4361823150 hasConceptScore W4361823150C86803240 @default.
• W4361823150 hasLocation W43618231501 @default.

• next